Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.57 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.57 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.57 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.57 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.57 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.57 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.57 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.57 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.57 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.57 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.57 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.52 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.51 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.51 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.51 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.51 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802062 | 0.98 | DRD3 (0.59) | MAPK1CHRM2ADRA2ACHRM1DRD1 | |
| Hydrochloric Acid SCHEMBL9352828 | 0.91 | SLC6A2 (0.51) | MAPK1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL9352969 | 0.89 | DRD3 (0.54) | MAPK1CHRM2ADRA2ACHRM1DRD1 | |
| Alcohol SCHEMBL7226806 | 0.89 | SLC6A2 (0.54) | MAPK1CHRM2ADRA2ACHRM1DRD1 | |
| Acetic Acid SCHEMBL2472607 | 0.89 | SLC6A2 (0.54) | MAPK1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL9563370 | 0.89 | SLC6A2 (0.50) | MAPK1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL8537416 | 0.89 | DRD3 (0.59) | MAPK1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL14814326 | 0.89 | SLC6A2 (0.51) | MAPK1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL12064952 | 0.87 | DRD3 (0.51) | MAPK1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL12064699 | 0.87 | DRD3 (0.51) | MAPK1CHRM2ADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326720-A1 | CAREBASTINE SALT AND USE OF SAME | CHENGDU SHIBEIKANG BIOMEDICAL TECH CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4520752-A1 | CAREBASTINE SALT AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213182-A1 | CAREBASTINE SALT AND USE THEREOF | 成都施贝康生物医药科技有限公司 | 2023-11-09 | — | — | WO | disclosed |
| CN-114890994-A | Histamine receptor antagonist and preparation thereof | 成都施贝康生物医药科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2011121099-A2 | PROCESS FOR THE PREPARATION OF 1-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-[4-(DIPHENYLMETHOXY)-1-PIPERIDINYL]-1-BUTANONE AND ACID ADDITION SALTS THEREOF | AREVIPHARMA GMBH (DE) | 2011-10-06 | — | — | WO | disclosed |
| EP-2371817-A1 | Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof | Arevipharma GmbH (DE) | 2011-10-05 | — | — | EP | disclosed |
| EP-0134124-B1 | PIPERIDINE DERIVATIVES | FORDONAL, S.A. (ES) | 1987-10-28 | — | — | EP | disclosed |
| US-4550116-A | ANTIALLERGENS, CARDIOVASCULAR AND RESPIRATORY DISORDERS | FORDONAL, S.A. (ES) | 1985-10-29 | — | — | US | disclosed |
| EP-0134124-A1 | Piperidine derivatives | FORDONAL, S.A. (ES) | 1985-03-13 | — | — | EP | disclosed |
| US-4377578-A | ANTIANAPHYLACTIC AGENTS, ANTIHISTAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1983-03-22 | — | — | US | disclosed |
| US-4261990-A | N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
| US-4250176-A | BENZIMIDAZOLE-2-ONE, BENZOTHIAZOL-2-ONE, OR BENZOXAZOL-2-ONE SUBSTITUTIONS, ANTIANAPHALACTIC AGENTS, ANTIHISTAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-02-10 | — | — | US | disclosed |
| US-4200641-A | ANTIANAPHYLACTIC AGENTS, ANTIHISTAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326720-A1 | CAREBASTINE SALT AND USE OF SAME | HRH4, SLC7A1, HRH1 | CHRM2 1195/4885ADRA2A 786/4885CHRM1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.